Atea Pharmaceuticals (AVIR) stock price is $4.45, down 0.34% on the day, as of Oct 21, 2026. It has a market cap of $356.22Mn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap356.22 Mn
P/E-2.16
Div. Yield0.00
Add ratio to table…
About
Atea Pharmaceuticals, Inc. is a late stage clinical biopharmaceutical company focused on discovering developing and commercializing novel orally administered antivirals to treat serious viral diseases. The company leverages its deep understanding of antiviral drug development medicinal chemistry biochemistry and virology to build a proprietary platform of nucleosides and nucleotides. This platform has yielded bemnifosbuvir a double prodrug nucleotide analog and AT 587…
Atea Pharmaceuticals, Inc. is a late stage clinical biopharmaceutical company focused on discovering developing and commercializing novel orally administered antivirals to treat serious viral diseases. The company leverages its deep understanding of antiviral drug development medicinal chemistry biochemistry and virology to build a proprietary platform of nucleosides and nucleotides. This platform has yielded bemnifosbuvir a double prodrug nucleotide analog and AT 587 another novel double prodrug nucleotide analog. Bemnifosbuvir is being developed in combination with ruzasvir for the treatment of hepatitis C virus while AT 587 is being advanced as a potential first direct acting antiviral for hepatitis E virus infection particularly in immunocompromised patient populations. For hepatitis C virus the bemnifosbuvir and ruzasvir combination is undergoing global Phase 3 clinical evaluation with the C BEYOND trial in the United States and Canada and the C FORWARD trial in regions outside of North America. The company anticipates submitting a new drug application to the US Food and Drug Administration in March 2027 contingent upon successful results from these Phase 3 studies.
Atea Pharmaceuticals, Inc. does not currently generate revenue from product sales as all its therapeutic candidates remain in clinical development and have not yet received regulatory approval for commercial sale. The company has no approved products on the market and therefore reports zero product revenue in its financial operations. Research and development activities represent the primary focus of the company's resource allocation including clinical trials for bemnifosbuvir and ruzasvir in hepatitis C virus infection and AT 587 for hepatitis E virus infection. Funding for these efforts is obtained through capital markets transactions to support the advancement of its antiviral pipeline toward potential regulatory approval and future commercialization.
Atea Pharmaceuticals, Inc. operates in the competitive antiviral therapeutics sector with a specific focus on hepatitis virus infections. In the hepatitis C virus treatment landscape the company faces established competitors including Gilead Sciences with its Epclusa regimen of sofosbuvir and velpatasvir and AbbVie with its Mavyret regimen of glecaprevir and pibrentasvir. Additional competitors include Merck's Zepatier combining elbasvir and grazoprevir and Gilead's Sovaldi as a foundational component in combination therapies. These current standards of care dominate the market having generated over two point five billion dollars in global net sales in 2025 with the United States accounting for approximately half of this total. Atea differentiates its bemnifosbuvir and ruzasvir regimen through its protease inhibitor free mechanism which avoids the drug interaction risks associated with protease inhibitor based therapies. The regimen is designed for a duration of eight weeks in non cirrhotic patients offering a shorter course than many existing twelve week regimens while maintaining pan genotypic efficacy across all hepatitis C virus genotypes. Preclinical and clinical data indicate a low risk of drug drug interactions with commonly prescribed medications such as proton pump inhibitors enhancing patient convenience and simplifying co medication management. In the hepatitis E virus space where no direct acting antiviral therapies are currently approved Atea aims to position AT 587 as a first in class treatment addressing significant unmet medical need. Hepatitis E virus infection poses a serious threat in immunocompromised populations including solid organ transplant recipients where it can rapidly progress to cirrhosis and liver failure. Current off label treatment with ribavirin is limited by significant side effects including anemia and teratogenic effects creating a clear opportunity for a novel direct acting antiviral. Atea's approach leverages its nucleoside nucleotide platform which builds on the proven success of similar mechanisms in treating human immunodeficiency virus hepatitis B virus and hepatitis C virus infections.
As a pre revenue company with no approved products Atea Pharmaceuticals, Inc. does not currently serve paying customers. However its target patient populations for potential future commercialization are clearly defined based on epidemiological data and medical need. For hepatitis C virus infection the World Health Organization estimates that approximately fifty million people globally live with chronic infection with about one million new infections occurring annually. In the United States the Centers for Disease Control and Prevention reports that as many as four million persons are infected with hepatitis C virus. The company focuses on non cirrhotic patients particularly those between twenty and forty nine years of age who represent a significant portion of the hepatitis C virus infected population. Additionally the company addresses patients with compensated cirrhosis who may benefit from an extended twelve week treatment duration as evaluated in its ongoing Phase 3 trials. For hepatitis E virus infection the filing cites an estimated nineteen point five million acute infections each year globally. Chronic hepatitis E virus infection develops in roughly three percent of immunocompromised individuals creating a substantial at risk population estimated at thirteen thousand five hundred cases annually in the United States and Europe based on solid organ and stem cell transplant statistics. The company specifically targets solid organ and stem cell transplant recipients people living with human immunodeficiency virus and those with hematologic or rheumatic conditions where hepatitis E virus can cause rapid progression to liver cirrhosis. In these populations current treatment options are limited to reducing immunosuppression which risks transplant rejection or off label ribavirin therapy associated with side effects such as dose dependent anemia dry cough teratogenic effects and dermatologic reactions. Upon achieving regulatory approval Atea anticipates that its therapies would be prescribed by specialists including hepatologists infectious disease specialists and transplant physicians. The medications would be distributed through specialty pharmacy networks and integrated into healthcare systems serving these patient communities to ensure appropriate access and follow up care.
Sector:HealthcareSector rationaleAtea Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel antivirals, specifically bemnifosbuvir and AT 587 for the treatment of hepatitis C and E. Its core business activity is the clinical development of pharmaceutical drugs, which falls directly under the Pharmaceuticals and Biotechnology industries within the Healthcare sector.Industry:BiotechnologyBiotechnologyPrimaryAtea Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies derived from biological science, specifically a proprietary platform of nucleosides and nucleotides. Its lead candidates, bemnifosbuvir and AT 587, are nucleotide analogs being developed to treat hepatitis C and hepatitis E.Classified using BQ-MICSCIK: 0001593899
Bull & bear
Investment Thesis
▲ Bull case
Atea Pharmaceuticals is uniquely positioned to capitalize on the persistent under-treatment of hepatitis C in the U.S., where only 53% of the estimated 160,000 new chronic infections receive therapy annually despite a growing prevalence that has nearly doubled from 2.5 million to approximately 4 million infected individuals since 2015. The company’s Phase III regimen demonstrates best-in-class attributes including an eight-week treatment duration for non-cirrhotic patients, high potency with 98% SVR12 in per-protocol analysis from Phase II, and a low risk of drug-drug interactions—particularly with proton pump inhibitors used by 35% of HCV patients—addressing a critical gap in current standard-of-care therapies like Epclusa. These differentiated features, validated through head-to-head trials against sofosbuvir/velpatasvir, align seamlessly with the expanding test-and-treat model endorsed by the CDC and bipartisan initiatives, which reduces barriers to care and could significantly increase treatment uptake beyond current levels. Management’s commercial strategy targets the highly concentrated U.S. prescriber base of ~6,000 specialists writing 80% of DAA prescriptions, enabling efficient commercialization with a lean 75-person sales force, while IQVIA market research indicates high prescriber intent to adopt the regimen for ~50% of their patients regardless of cirrhosis status. Financially, the company enters 2026 with $301.8 million in cash and investments, projecting a cash runway through 2027, which fully funds the completion of both pivotal Phase III HCV trials (C BEYOND topline midyear, C FORWARD topline year-end) and supports early-stage HEV development without near-term dilution risk. The HEV program targeting immunocompromised patients—estimated at 13,500 annual at-risk cases in the U.S. and Europe from a pool of 450,000 high-risk individuals—represents a $750 million to $1 billion annual orphan market opportunity with no approved therapies, where 85-87 has shown potent in vitro activity against HEV genotype 3 and clinical ribavirin resistance, supported by clean preclinical safety and efficient conversion to active triphosphate in human hepatocytes. Together, these factors suggest the market is underestimating Atea’s ability to capture share in a large, growing HCV market while simultaneously launching a first-in-class HEV franchise that could drive multi-year revenue expansion beyond current consensus expectations.
Atea Pharmaceuticals is uniquely positioned to capitalize on the persistent under-treatment of hepatitis C in the U.S., where only 53% of the estimated 160,000 new chronic infections receive therapy annually despite a growing prevalence that has nearly doubled from 2.5 million to approximately 4 million infected individuals since 2015. The company’s Phase III regimen demonstrates best-in-class attributes including an eight-week treatment duration for non-cirrhotic patients, high potency with 98% SVR12 in per-protocol analysis from Phase II, and a low risk of drug-drug interactions—particularly with proton pump inhibitors used by 35% of HCV patients—addressing a critical gap in current standard-of-care therapies like Epclusa. These differentiated features, validated through head-to-head trials against sofosbuvir/velpatasvir, align seamlessly with the expanding test-and-treat model endorsed by the CDC and bipartisan initiatives, which reduces barriers to care and could significantly increase treatment uptake beyond current levels. Management’s commercial strategy targets the highly concentrated U.S. prescriber base of ~6,000 specialists writing 80% of DAA prescriptions, enabling efficient commercialization with a lean 75-person sales force, while IQVIA market research indicates high prescriber intent to adopt the regimen for ~50% of their patients regardless of cirrhosis status. Financially, the company enters 2026 with $301.8 million in cash and investments, projecting a cash runway through 2027, which fully funds the completion of both pivotal Phase III HCV trials (C BEYOND topline midyear, C FORWARD topline year-end) and supports early-stage HEV development without near-term dilution risk. The HEV program targeting immunocompromised patients—estimated at 13,500 annual at-risk cases in the U.S. and Europe from a pool of 450,000 high-risk individuals—represents a $750 million to $1 billion annual orphan market opportunity with no approved therapies, where 85-87 has shown potent in vitro activity against HEV genotype 3 and clinical ribavirin resistance, supported by clean preclinical safety and efficient conversion to active triphosphate in human hepatocytes. Together, these factors suggest the market is underestimating Atea’s ability to capture share in a large, growing HCV market while simultaneously launching a first-in-class HEV franchise that could drive multi-year revenue expansion beyond current consensus expectations.
Atea Pharmaceuticals faces significant execution and competitive risks in its HCV Phase III program that the market may be overlooking, particularly regarding the divergent primary endpoint analyses between C BEYOND (modified intent-to-treat per FDA preference) and C FORWARD (per-protocol per EMA preference), which creates regulatory uncertainty and increases the likelihood of conflicting results that could delay or jeopardize simultaneous global approvals. The company’s reliance on a non-inferiority design with a 5% margin against Epclusa—rather than seeking superiority—limits upside potential in a market where payers and physicians increasingly demand demonstrably better outcomes, especially given that current standard-of-care regimens already achieve high SVR rates, leaving little room for differentiation beyond convenience factors like shorter duration or no food effect. Commercial headwinds are underappreciated, as the DAA market has experienced sustained net pricing pressure over the past two to three years, with legacy providers like Gilead maintaining near 50/50 market share with Epclusa despite incremental price increases, suggesting Atea may struggle to gain meaningful share without aggressive pricing concessions that could undermine early profitability projections. The commercial launch strategy, while targeting a focused prescriber base, assumes rapid adoption based on Phase II physician intent data that may not translate to real-world prescribing behavior, particularly given the inertia in specialty prescribing patterns and the need to displace entrenched therapies through costly detailing efforts in a market where payers are increasingly skeptical of premium pricing for incremental benefits. Furthermore, the HEV program, while scientifically promising, remains highly speculative with no in-human data yet, and the plan to initiate a first-in-human study midyear 2026 followed by a possible Phase II/III in 2027 implies a long and uncertain path to commercialization, during which time the $750 million to $1 billion market opportunity estimate may not materialize if alternative therapies emerge or if the at-risk immunocompromised population does not develop chronic HEV at projected rates. Finally, the company’s financial position, while currently strong with $301.8 million in cash, depends on successful execution of costly Phase III trials and timely regulatory submissions, with any delay in C FORWARD enrollment (expected midyear) or topline data (year-end) risking a faster-than-anticipated cash burn that could truncate the runway before 2027, especially if milestone payments to Merck for the in-licensed HCV regimen are triggered earlier than anticipated upon NDA submission and approval.
Atea Pharmaceuticals faces significant execution and competitive risks in its HCV Phase III program that the market may be overlooking, particularly regarding the divergent primary endpoint analyses between C BEYOND (modified intent-to-treat per FDA preference) and C FORWARD (per-protocol per EMA preference), which creates regulatory uncertainty and increases the likelihood of conflicting results that could delay or jeopardize simultaneous global approvals. The company’s reliance on a non-inferiority design with a 5% margin against Epclusa—rather than seeking superiority—limits upside potential in a market where payers and physicians increasingly demand demonstrably better outcomes, especially given that current standard-of-care regimens already achieve high SVR rates, leaving little room for differentiation beyond convenience factors like shorter duration or no food effect. Commercial headwinds are underappreciated, as the DAA market has experienced sustained net pricing pressure over the past two to three years, with legacy providers like Gilead maintaining near 50/50 market share with Epclusa despite incremental price increases, suggesting Atea may struggle to gain meaningful share without aggressive pricing concessions that could undermine early profitability projections. The commercial launch strategy, while targeting a focused prescriber base, assumes rapid adoption based on Phase II physician intent data that may not translate to real-world prescribing behavior, particularly given the inertia in specialty prescribing patterns and the need to displace entrenched therapies through costly detailing efforts in a market where payers are increasingly skeptical of premium pricing for incremental benefits. Furthermore, the HEV program, while scientifically promising, remains highly speculative with no in-human data yet, and the plan to initiate a first-in-human study midyear 2026 followed by a possible Phase II/III in 2027 implies a long and uncertain path to commercialization, during which time the $750 million to $1 billion market opportunity estimate may not materialize if alternative therapies emerge or if the at-risk immunocompromised population does not develop chronic HEV at projected rates. Finally, the company’s financial position, while currently strong with $301.8 million in cash, depends on successful execution of costly Phase III trials and timely regulatory submissions, with any delay in C FORWARD enrollment (expected midyear) or topline data (year-end) risking a faster-than-anticipated cash burn that could truncate the runway before 2027, especially if milestone payments to Merck for the in-licensed HCV regimen are triggered earlier than anticipated upon NDA submission and approval.